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| INTRODUC TI ON
Blood clotting is preventing blood loss as well as infiltration of microbes. Factor VIIa (FVIIa) is one key enzyme in the initiation phase of the coagulation cascade, 1,2 forming a complex with tissue factor (TF) exposed upon injury. The role of TF is to promote FVII conversion to FVIIa by localization as well as to convert zymogenlike FVIIa to the active conformation and make it an efficient catalyst of FVII, factor X, and factor IX activation. 3 Attempts at creating less TF-dependent FVIIa variants, that is, molecules with a builtin stabilization of the active conformation and elevated intrinsic enzymatic activity, have among other variants given rise to V21D/ E154V/M156Q-FVIIa (FVIIa DVQ , chymotrypsinogen numbering).
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Analogue FVIIa DVQ was originally developed with the aim of offering a more potent FVIIa-based treatment of hemophilia. 5 Even though it proved very efficacious in the clinical trials, 6 FVIIa DVQ provoked the immune system in some patients, and the clinical trials were terminated due to the detection of antidrug antibodies. 7 FVIIa DVQ was more proteolytically active compared to FVIIa, even though it can be further stimulated by TF, retained the substrate specificity of FVIIa, and efficiently promoted thrombin and fibrin generation. 4, 8 The need for a monoclonal antibody that could be used to quantify FVIIa DVQ in clinical samples also containing endogenous FVII(a) led to the identification of mAb4F5. This antibody also turned out to be a powerful tool for studying FVIIa allostery.
In this study, we characterized mAb4F5 binding to FVIIa DVQ , which is of very high affinity (K d <100 pmol/L), and its functional consequences. We have determined the crystal structure of the Fab fragment of mAb4F5 (Fab4F5) and described the potential antigen-combining sites. We used molecular docking, restrained by experimental smallangle X-ray scattering (SAXS), to build a model of the FVIIa DVQ :Fab4F5 complex, which possessed considerable stability. The binary complex explains and supports the unique selectivity and, in an allosteric context, functional consequences of Fab4F5 association with FVIIa DVQ . 
| MATERIALS AND METHODS

| Expression and purification of FVIIa
| Characterization of FVIIa variant binding to mAb4F5 by surface plasmon resonance (SPR)
The binding analyses were run on a Biacore 3000 instrument (Biacore AB, Uppsala, Sweden) at 25°C. Antimouse IgG1, 30 μg/mL in 10 mmol/L sodium acetate, pH 5.0, was immobilized onto a CM5 sensor chip using amine coupling chemistry and used throughout the whole series. The flow rate was 5 μL/min and the injection time Binding kinetics were evaluated using BIAevaluation 4.1 software.
| Crystallization and Data Collection
Crystallizations of Fab4F5 were performed using the sitting drop 
| Crystal structure determination and refinement
The structure of Fab4F5 was solved by molecular replacement electron density maps were examined, and the protein model was manually adjusted after each refinement cycle using the molecular graphics program COOT. 16 Solvent molecules were added using an F o -F c map contoured at 2.5 σ in the final refinement step. The majority of residues in the final model have allowed stereochemistry in a Ramachandran plot as shown by PROCHECK. 17 The final model refinement statistics are summarized in (Table 2 ). However, all 3 mutations were required for optimal affinity. Regular FVIIa was only weakly recognized by mAb4F5.
| SAXS and structural modeling of
Furthermore, it was evident that K20E-FVIIa DVQ was poorly recognized by mAb4F5. Thus, residues Lys20 and Asp21 in FVIIa DVQ were crucial components of the epitope for mAb4F5. Interestingly, The binding of mAb4F5 to FVIIa DVQ eliminated >99% of the amidolytic enzyme activity, whereas the activity of FVIIa was unaffected by the presence of mAb4F5. This is in line with the hypothesis that mAb4F5 binding to its epitope, comprising at least 2 residues close to the tail N-terminus (Ile16), prevents tail insertion into the activation pocket. FVIIa DVQ is in a conformational equilibrium between an active form with the N-terminus inserted into the activation pocket and a latent form with an exposed N-terminal tail. Conceivably, mAb4F5 grabs hold of its epitope when exposed and accessible and thereby prevents tail reinsertion and precludes FVIIa DVQ enzymatic activity. In other words, mAb4F5 binding locks FVIIa DVQ in the zymogen-like conformation with a truly "homeless" N-terminus.
| Crystal structure of Fab fragment of mAb4F5
The crystal structure of Fab4F5 was solved with the molecular replacement method and refined to high resolution (1.81 Å) with an R factor of 20.9% and a R free factor of 24.7% (Table 1 ). There were The average temperature factor for Fab4F5 was 36.6 Å. This structure had a good stereochemical geometry with the root mean square deviation values for bond lengths of 0.009 Å and for bond angles 1.3°. In addition, 99.3% of the residues were in the allowed region of the Ramachandran plot ( Table 1 ).
The Fab4F5 structure has the typical immunoglobulin fold consisting of V L and C L domains of the light chain and V H and C H domains of the heavy chain, with elbow angles of 136.7°. The conformation of the Fab4F5 CDRs is well defined even though no antigen is bound at the combining site. Three CDRs are found on the light chain (L1-L3) and 3 on the heavy chain (H1-H3) (Figure 1 ). Among them, the length of H2 (15 residues) in Fab4F5 is shorter than the usual length (16) (17) (18) (19) residues) seen in other Fab variants. 26, 27 There is a long groove about 15.6 Å wide including 1 hydrophobic pocket (Leu96L, Kabat numbering) and 1 charged pocket (Asp95H and Tyr99H). These 2 pockets plus Tyr98H presumably constitute the antigen-binding sites (Figure 2 ).
| Docking analysis of interactions between FVIIa DVQ and Fab4F5
A crystal structure of FVIIa DVQ in complex with Fab4F5 would be ideal to understand in detail the molecular interactions between the 2 proteins. Unfortunately, the crystallization of such a complex failed despite numerous trials (using Gla-domainless FVIIa DVQ obtained by digestion with cathepsin G). However, the availability of the current Fab4F5 structure and a published crystal structure of FVII in its zymogen form 20 allowed us to build a molecular model of the FVIIa DVQ :Fab4F5 complex using the protein-protein docking program HADDOCK.
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HADDOCK allows the use of the constraints identified from mutagenesis studies during the molecular docking. On the FVIIa DVQ side, we identified residues Lys20 and Asp21 as the key residues for Fab4F5 interaction. On the Fab4F5 side, the CDR loops are the typical antigen-combining site. The heavy-chain H3 loop of antibodies is typically the most important for antigen recognition. 28 The CDR H3 loop of Fab4F5 has 9 residues, which is the typical length of H3 loops for antiprotein antibodies. 29 This length is the same as that of Fab112, which binds to the autolysis loop of urokinase-type plasminogen activator. 30 In contrast to Fab4F5, an antimatriptase antibody (FabE2, PDB code: 3BN9) has a very long H3 loop (18 residues), which inserts into the canyon-like active site cleft and occupies the subsite pockets (S1-S4). 31 Therefore, the length of the CDR H3 loop of mAb4F5 suggests that the H3 most likely does not bind to the active site of FVIIa DVQ . Tyrosine is the most prominent type of amino acid residue involved in the mAb4F5-FVIIa DVQ interaction. This is a feature commonly found in the interface between an antibody and its macromolecular antigen. 32 As noted previously, the side chain of tyrosine is large enough to occupy large volumes of space with only a few torsion angles, and it can also form hydrogen bonds, hydrophobic interactions, and attractive electrostatic interactions with positively charged groups. Moreover, the uncharged side chain of tyrosine avoids electrostatic repulsion effects, and its midrange hydrophilicity allows it to adapt favorably to both hydrophilic and hydrophobic environments. 
| SAXS structure shows that FVIIa DVQ interacts with Fab4F5 to form a stable complex in solution
We next used SAXS to model the 3-dimensional structure of the FVIIa DVQ :Fab4F5 complex. The complex was assembled using a 2-fold molar excess of Fab4F5 and purified by gel filtration chromatography in a buffer (50 mmol/L Tris, 150 mmol/L NaCl, pH 7.4). We observed that FVIIa DVQ :Fab4F5 was a monomer on a Superdex 200 10/300 GL column with a retention volume of about 13.4 mL, which is consistent with the complex's estimated molecular mass of 84 kDa. The scattering data were collected from the sample of 3 mg/mL ( Figure 4A ), which showed no radiation damage and higher signal-to-noise ratio. The clear linear behavior of the Guinier plot also strongly suggested that FVIIa DVQ :Fab4F5 is a monodisperse protein (inset of Figure 4A ), and its radius of gyration (R g ) is 40.2 Å.
According to Kratky analysis, there is a peak with a height of around 9.8 at low q values, which returns to zero at high q values, but at a slower rate than expected from compact proteins. This indicates an intact, folded conformation of FVIIa DVQ :Fab4F5 with some flexibility in solution ( Figure 4B ).
To reconstruct the molecular envelope of the FVIIa DVQ :Fab4F5 complex from the scattering curve, it is important to know whether molecular symmetry is present in the particle. As mentioned previously, the retention volume of FVIIa DVQ :Fab4F5 showed that this complex was monomeric. Thus, we reconstructed the 
Leu96L
FVIIa DVQ :Fab4F5 molecular envelope using the program DAMMIF with P1 symmetry. 36 We used DAMAVER to generate the averaged molecular envelope. 23 The model was then generated based on the docking results and built into the averaged molecular envelope of the FVIIa DVQ :Fab4F5 using the program CHIMERA. 37 In the overall structure, the FVIIa DVQ :Fab4F5 complex envelope 
| PROTEIN DATA BANK ACCESSION NUMBER
The coordinate of the Fab4F5 structure has been deposited in the Protein Data Bank (PDB code: 5YUP). 
ACKNOWLEDGMENTS
RELATIONSHIP DISCLOSURE
The authors report nothing to disclose.
AUTHOR CONTRIBUTIONS
LJ was involved in protein preparation, crystallization, structure determination, and analysis; XX participated in SAXS structure analysis. JL participated in molecular docking and analysis. EP Gla Gla
